TY - JOUR
T1 - Evaluation of the effects of human leukocyte IFN-α on the immune response to the HBV vaccine in healthy unvaccinated individuals
AU - Rizza, Paola
AU - Capone, Imerio
AU - Urbani, Francesca
AU - Montefiore, Enrica
AU - Rapicetta, Maria
AU - Chionne, Paola
AU - Candido, Angela
AU - Tosti, Maria Elena
AU - Grimaldi, Maria
AU - Palazzini, Ernesto
AU - Viscomi, Giuseppe
AU - Cursaro, Carmela
AU - Margotti, Marzia
AU - Scuteri, Alessandra
AU - Andreone, Pietro
AU - Taylor, Elisabeth
AU - Haygreen, Elisabeth A.
AU - Tough, David F.
AU - Borrow, Persephone
AU - Selleri, Marina
AU - Castilletti, Concetta
AU - Capobianchi, Maria
AU - Belardelli, Filippo
PY - 2008/2/20
Y1 - 2008/2/20
N2 - HBV vaccine needs 3 injections over 6 months to induce immunity. Thus, the use of adjuvants capable of inducing earlier immune protection would be highly desirable. Most adjuvants may act by inducing cytokines, and among them, type I interferons (IFNs), deserve a special attention in view of the potent immunomostimulatory activity observed in mouse models and on dendritic cell functions. The aim of the present trial was to evaluate the effects of IFN-α administered as an adjuvant of HBV vaccine in healthy unvaccinated individuals. No significant enhancing effect on the antibody response was observed, in spite of an early and transient upregulation of costimulatory molecule expression on peripheral blood mononuclear cells, which may be suggestive of an IFN-mediated activation of antigen presenting cells. We conclude that, under the conditions used in this trial, natural IFN-α does not act as an adjuvant of the HBV vaccine in healthy unvaccinated individuals.
AB - HBV vaccine needs 3 injections over 6 months to induce immunity. Thus, the use of adjuvants capable of inducing earlier immune protection would be highly desirable. Most adjuvants may act by inducing cytokines, and among them, type I interferons (IFNs), deserve a special attention in view of the potent immunomostimulatory activity observed in mouse models and on dendritic cell functions. The aim of the present trial was to evaluate the effects of IFN-α administered as an adjuvant of HBV vaccine in healthy unvaccinated individuals. No significant enhancing effect on the antibody response was observed, in spite of an early and transient upregulation of costimulatory molecule expression on peripheral blood mononuclear cells, which may be suggestive of an IFN-mediated activation of antigen presenting cells. We conclude that, under the conditions used in this trial, natural IFN-α does not act as an adjuvant of the HBV vaccine in healthy unvaccinated individuals.
KW - Adjuvant
KW - Interferon
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=39149107091&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=39149107091&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2007.12.044
DO - 10.1016/j.vaccine.2007.12.044
M3 - Article
C2 - 18249478
AN - SCOPUS:39149107091
VL - 26
SP - 1038
EP - 1049
JO - Vaccine
JF - Vaccine
SN - 0264-410X
IS - 8
ER -